CytomX Therapeutics, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for CTMX, updated each market day.
CTMX AI Sentiment
AI sees no strong directional signal for CytomX Therapeutics, Inc. stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About CytomX Therapeutics, Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Sector
Exchange
Market Cap
$916,591,790
Cap Tier
Employees
69
Headquarters
SOUTH SAN FRANCISCO, CA
Listed Since
Oct. 8, 2015
Website
CTMX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
CTMX Volatility
CytomX Therapeutics, Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
